No Market, No Attention: Pernicious Anemia and the Cost of Invisibility

I. A Patient’s Half-Century of Missed Diagnosis

Starting at age 17 — around 1974 — a woman found out repeatedly that she was anemic, not through medical care but because blood banks turned her away. More than half the time she tried to donate blood, the screening test flagged her hemoglobin as too low. When she mentioned this to a physician, the response was a casual suggestion to take iron tablets. No one ordered a workup to determine why the anemia kept recurring. No one tracked the finding across visits. The encounters closed, and the question closed with them.

This pattern held for decades. Laboratory work ordered for fatigue returned mostly-normal findings that generated no investigation. Fatigue itself — the kind that makes sustained effort feel like moving through resistance — was so constant that it registered as normal. When you have never experienced adequate energy, there is no baseline against which to measure the deficit. The symptoms accumulated without a name.

In 2018, she asked for a specific test: intrinsic factor antibody. The result came back positive. A positive intrinsic factor antibody is, in clinical terms, essentially diagnostic for pernicious anemia — the test has a false positive rate below five percent, making it among the most specific results in autoimmune medicine. The provider initiated B12 injections. Once monthly. No loading dose. No protocol adjustment for neurological involvement, which clinical guidelines address specifically. No explanation of what pernicious anemia meant, what damage it caused, or why consistent treatment mattered. The patient, given no reason to treat the injections as urgent, sometimes missed months. Nothing in her experience with clinicians suggested she should do otherwise.

During this same period, she had two ischemic strokes (2016 and 2018). After the first stroke, a cardiologist performed a transesophageal echocardiogram, which found no embolic source. After the second, evaluation at Barrow Neurological Institute in Phoenix found no identifiable cause for either event. The emergency workup on July 12-conducted three months after a confirmed PA diagnosis-included cardiac markers, coagulation studies, and a comprehensive metabolic panel. It did not include B12 or homocysteine. In a patient with a confirmed autoimmune B12 deficiency presenting with a second cryptogenic stroke, that gap represents a failure of clinical integration, independent of what those results would have shown.

In the spring of 2024, she developed urticaria and stopped all supplements, including B12 injections, to identify a possible cause. Within approximately two months, her balance deteriorated to the point where she could not walk two steps. She was hospitalized for stroke assessment. The hospital discharged her with a diagnosis of benign paroxysmal positional vertigo. She was referred to physical therapy. The physical therapist, after several sessions, noted that the presentation did not fit BPPV and appeared neurological in origin. The patient, who by then had spent years educating herself about B12 metabolism, recognized the connection. She resumed injections. The balance impairment resolved.

She is now in her late sixties. To maintain proprioception and basic balance, she requires an injection every two days. Much of the neurological damage that accumulated across the decades before adequate treatment began has not reversed.

Contents

No Market, No Attention: Pernicious Anemia and the Cost of Invisibility
I. A Patient’s Half-Century of Missed Diagnosis
II. A Treatable Disease With Poor Outcomes
III. Medical Attention Follows Commercial Activity
IV. B12 Generates None of the Signals Medicine Responds To
V. The Diagnostic Gap Runs Through Both Sexes
VI. The Disease Undermines Its Own Diagnosis
VII. A Structural Problem, Not a Conspiracy

Over that same span of years, she accumulated a significant burden of diagnosed conditions. Several carry documented associations with B12 deficiency and pernicious anemia in the clinical literature:

Two cryptogenic ischemic strokes (2016, 2018), with no embolic source identified after full workup
Peripheral neuropathy, persistent
Rheumatoid arthritis (diagnosed 2008), with chronic joint involvement
Osteopenia, documented on bone density scanning
Fibromyalgia (diagnosed 2000)
Severe iron deficiency requiring intravenous infusion
Celiac disease, which shares autoimmune mechanisms with PA and co-occurs at elevated rates
Obstructive sleep apnea
Cognitive and mood symptoms across multiple decades

We don’t know whether those relationships caused or contributed to her condition, or the degree to which they affected its course. The research that would establish this does not exist. That absence of research is not incidental. It is, in part, a product of the same structural failure this article describes.

The case described here is real. The patient is the author.

This case is not unusual. That is the point of this article.

II. A Treatable Disease With Poor Outcomes

Pernicious anemia is eminently treatable with inexpensive, safe, and highly effective vitamin B12 therapy — a standard intervention available for nearly a century. The diagnostic criteria and management protocols are well established in medical literature, leaving no substantive dispute about the underlying science.

Yet patients routinely endure years, even decades, of delayed diagnosis. A landmark prospective study published in the Archives of Internal Medicine found that 1.9 percent of people over 60 had unrecognized and untreated pernicious anemia, with rates as high as 4.3 percent in Black women and 4.0 percent in white women. The study estimated that nearly 800,000 elderly Americans were living with the undiagnosed condition at the time of the research. For many patients, the root cause is never identified at all. Neurological damage often becomes irreversible before treatment begins, positive diagnostic tests are overlooked, and symptoms are frequently misattributed to psychiatric conditions.¹

The scale of the broader problem is substantial. Vitamin B12 deficiency — of which pernicious anemia is the most common clinically recognized cause in adults, accounting for an estimated 20 to 50 percent of cases — affects roughly 6 percent of people under 60 and up to 20 percent of those over 60 in the United States and United Kingdom. Globally, the burden is far larger: prevalence reaches 40 percent in parts of Latin America and 70 to 80 percent in parts of Africa and India, driven primarily by dietary insufficiency. Pernicious anemia itself affects approximately 0.1 percent of the general population worldwide, rising to nearly 2 percent among those over 60. These figures are almost certainly under estimates, given the diagnostic challenges this article examines.²

Two prior articles traced the historical origins of the diagnostic gap: the observational bias that originally defined pernicious anemia through its terminal nineteenth-century presentation; the enduring nomenclature that fixed attention on late-stage hematologic findings rather than the underlying autoimmune process; the fragmentation across specialties — hematology, neurology, psychiatry, and primary care — that diffuses accountability; and laboratory reductionism, which permits a normal serum B12 level to halt investigation despite clear neurological red flags. A 19th-Century Disease Model Still Shapes Modern Care and Pernicious Anemia: A History of Observation, Misdiagnosis, and Systemic Blind Spots. These systemic shortcomings, thoroughly documented, continue to shape contemporary care.

This article examines a different layer of the same problem. The question is not only why the historical blind spots developed, but why they have never been corrected. History explains how the problem was created, but doesn’t explain the persistence.

That something else is the structure of attention and incentive in modern medicine — and pernicious anemia’s position within it.

III. Medical Attention Follows Commercial Activity

Medical knowledge does not distribute itself evenly across diseases or treatments. What gets researched, taught, emphasized in clinical training, and kept salient in day-to-day practice is shaped by more than scientific importance. It is shaped by where money flows, and by the commercial and institutional activity that money generates.

Pharmaceutical companies fund a substantial share of continuing medical education. In the United States, industry sponsorship accounts for up to 65 percent of CME program revenue. The influence extends beyond the financial. Studies show that physician prescribing patterns shift after attendance at commercially sponsored CME events, with sponsored products receiving preferential uptake. One analysis estimated that pharmaceutical companies see a return of $3.56 in drug sales for every dollar invested in CME. The mechanism operates even when CME is advertised as unrestricted funding, because sponsors shape speaker selection, content framing, and topic choice in ways that align with their commercial interests.

Pharmaceutical sales representatives — detailing — reinforce the same dynamic outside the classroom. Detailing accounts for roughly 60 percent of the pharmaceutical industry’s global promotional spend. Its effect on prescribing behavior is measurable. A natural experiment across approximately 25,000 physicians at nineteen academic medical centers found that when institutions restricted detailing, the market share of promoted drugs fell by 8.7 percentage points. Physicians shifted toward cheaper generics across eight therapeutic classes. The implication is direct: commercial promotion keeps specific diagnoses and specific treatments salient in clinical practice. Its absence has the opposite effect.

Research funding follows the same pattern. Patent status is among the most powerful predictors of whether a drug or treatment receives substantial investment. Off-patent compounds and nutritional interventions attract minimal private research funding because they offer no return on investment. For treatments with no patent protection and no commercial future, private capital does not appear.

The funding picture for vitamin B12 research illustrates this directly. What NIH RePORTER shows for B12 deficiency is a modest collection of publicly funded projects — federal grants, not private investment. Private capital in B12 concentrates in supplement manufacturing and commercial applications, not in clinical research into deficiency, diagnosis, or treatment adequacy. The contrast with vitamin D is instructive: vitamin D attracted supplement manufacturers, testing laboratories, and a broad commercial research hypothesis about its role in cancer, cardiovascular disease, and autoimmune conditions, generating hundreds of active research projects and substantial combined funding across public and private sources. Vitamin B12, unpatentable and inexpensive, attracted none of that pharmaceutical-scale commercial interest. The gap in research investment reflects a gap in commercial potential, not a gap in clinical importance.

In a medical system where attention follows commercial activity, a treatment with none of that activity is effectively invisible.

IV. B12 Generates None of the Signals Medicine Responds To

Vitamin B12 fails every test by which modern medicine sustains attention on a treatment, simultaneously and completely.

It is unpatentable. Injectable cyanocobalamin and hydroxocobalamin have been off-patent for decades. No manufacturer holds exclusive rights. No one has a financial interest in promoting B12 over a competitor product, because there is no competitor product in the relevant sense — no branded version seeking market share, no company funding research to demonstrate superiority.

It is inexpensive. The cost of B12 injections is negligible compared to virtually any pharmaceutical alternative. The economics that drive research funding, CME sponsorship, and clinical promotion simply do not exist.

It generates no commercial prescribing cascade. A prescribing cascade occurs when a drug causes an adverse reaction that is misinterpreted as a new condition, prompting an additional prescription. The clinical literature has documented dozens of such pathways — calcium channel blockers causing edema treated with diuretics, anticholinergic drugs causing constipation treated with laxatives, one class of medication generating the market for another. B12 produces none of this. It corrects the deficiency and exits the clinical story. No downstream prescriptions. No new conditions. No ongoing revenue.

It generates no ongoing clinical narrative once it works. A drug that causes side effects stays in the literature through adverse event reporting, safety monitoring, guideline revisions, and specialist follow-up. A drug that creates new conditions generates its own research ecosystem. B12 supplementation, when adequate, resolves symptoms and produces no signal requiring further management. It disappears from clinical view precisely because it succeeds.

Proton pump inhibitors illustrate the contrast. PPIs are among the most widely used medications in the world — hundreds of millions of users globally, now available over the counter in many countries. Long-term PPI use impairs vitamin B12 absorption, a documented and well-established effect. The monitoring guidance exists. In practice, B12 status is rarely checked in long-term PPI users. The drug that creates the depletion has an enormous commercial infrastructure behind it. The nutrient depleted by that drug has none.⁹

Metformin presents the same pattern in sharper relief, because the monitoring gap there is particularly well documented. Metformin is the most widely prescribed diabetes medication in the world. Its capacity to impair B12 absorption is established and has been recognized in clinical literature for decades. The American Diabetes Association’s Standards of Care introduced a specific recommendation for periodic B12 testing in metformin patients in 2017, and the recommendation has been retained in subsequent editions. Despite this, monitoring rates remain low. An analysis of ambulatory care settings found that the majority of metformin patients were not screened for B12 despite guideline recommendations. A trend analysis of a real-world database demonstrated that B12 testing among metformin patients actually declined between 2000 and 2020 — moving in the wrong direction as evidence accumulated.⁸

A guideline recommendation that generates declining compliance over two decades is not a knowledge failure. It is a failure of attention. No commercial infrastructure exists to reinforce the recommendation, train physicians on its importance, or keep B12 monitoring in clinical memory between guideline publications. The guideline remained unused in actual practice.

The same attention deficit extends past diagnosis into treatment. Guidelines for confirmed pernicious anemia specify lifelong intramuscular B12 replacement and explicitly permit more frequent injections when symptoms persist or return before the next scheduled dose. In practice, many patients with confirmed diagnoses receive rigid adherence to fixed schedules regardless of symptom recurrence.

A large patient survey conducted by the Pernicious Anaemia Society found that 92 percent of confirmed PA patients experienced return of symptoms before their next scheduled injection, and 64 percent rated their overall treatment as inadequate. A subsequent study of 971 patients found that 52 percent were managing on more frequent injection schedules than guidelines specify — often self-directed, sourced independently, and conducted outside medical supervision.⁷⁴

Qualitative evidence gathered for the 2024 NICE guideline review found that patients described being made to feel “shameful” for requesting more frequent treatment, with clinicians defaulting to fixed schedules and dismissing symptom reports that contradicted them.⁵

Eight months after the 2024 NICE guideline explicitly endorsed individualized dosing for patients with persistent symptoms, patient surveys and practitioner reports indicated most practices had not changed. The guideline sat in a document. Nothing was pushing it to operationalize.⁶

The same failure of awareness reappears at the treatment stage. The diagnosis fails because there is no commercial infrastructure that keeps B12 visible in clinical practice. When the diagnosis finally occurs, the treatment fails for the same reason.

V. The Diagnostic Gap Runs Through Both Sexes

Pernicious anemia is an autoimmune disease with a female predominance of approximately two to one. This means more women are undiagnosed in absolute numbers. It does not mean men are spared the diagnostic failure.

Studies of diagnostic delay in pernicious anemia report median intervals of five to six years from first presentation to formal diagnosis — and that figure measures only the visible portion of the delay, from first clinical contact or first abnormal laboratory finding to diagnosis. It does not capture the years before that, when symptoms were present but either not brought to a physician, or brought to a physician and attributed to something else entirely. The subclinical phase of pernicious anemia — the period during which autoimmune gastric destruction is progressing but overt symptoms have not yet been recognized — is estimated in the systematic literature at approximately ten years. The documented delay begins after that phase ends. The real latency between disease onset and diagnosis is longer than any study has measured, because the methodology for measuring it requires a starting point that the system rarely documents.

The female and male pathways through this failure are different in mechanism while similar in outcome. Women presenting with fatigue, cognitive changes, mood disturbance, and neuropathy encounter a medical system with a well-documented historical tendency to attribute diffuse, non-specific symptom profiles in women to psychological causes. The symptom cluster of early pernicious anemia — before anemia is established and unmistakable — maps almost precisely onto the presentations most likely to be redirected toward a psychiatric diagnosis. Depression has a robust commercial ecosystem. Anxiety has a robust commercial ecosystem. B12 deficiency does not. The patient who should receive an intrinsic factor antibody test receives a prescription for an antidepressant instead, not through malice but through the structural logic of a system that has diagnostic infrastructure for one and not the other.

Men with the same symptom profile are less likely to seek care at all, and when they do, the lower prior probability that a physician assigns to autoimmune disease in a male patient may delay investigation further. The presentation at diagnosis, when it comes, is often more advanced. The documentation on sex-disaggregated diagnostic delay in pernicious anemia specifically is limited — the research that would characterize this precisely has not been adequately funded, for reasons this article has already described. What the available data show is that both sexes accumulate significant damage before diagnosis, through different failure modes operating on the same inadequate infrastructure.

It is also worth noting that pernicious anemia presents without anemia in a meaningful proportion of cases. A foundational 1988 study in the New England Journal of Medicine found that 28 percent of patients with neuropsychiatric abnormalities due to cobalamin deficiency had no anemia or macrocytosis — roughly one in four. The study examined cobalamin deficiency broadly rather than pernicious anemia exclusively, but its findings have been accepted and applied in PA literature ever since. Neurological damage from B12 deficiency is established in the research literature as capable of preceding hematologic abnormalities. The name of the disease, and the clinical training built around it, centers anemia. A patient with significant neurological involvement and a normal blood count does not fit the clinical picture physicians have been taught to recognize. The disease’s own name is part of the diagnostic barrier.³

Both sexes accumulate significant damage before diagnosis — through different failure modes operating on the same inadequate infrastructure.

VI. The Disease Undermines Its Own Diagnosis

There is a final structural element that deserves explicit statement, because it is the most consequential and the least discussed.

B12 deficiency causes neurological damage that includes cognitive slowing, memory impairment, and difficulty with sustained analytical thinking. The disease partially disables the cognitive capacity required to navigate a system that has placed the diagnostic burden on the patient.

The patient who eventually identifies her own diagnosis — who researches laboratory data, traces physiological dynamics, insists on specific tests, catches results that ordering physicians missed — does so against the resistance of the disease itself. The capacity to do that work is precisely what the deficiency degrades. Patients who are most severely affected are least able to mount the self-advocacy that the system requires of them. The diagnostic failure is self-reinforcing in the most direct possible way: the longer it persists, the harder it becomes to correct.

The case described here illustrates this directly. The investigation that finally converged on the correct picture became possible only when she reached a life stage where reduced responsibilities freed the cognitive and physical resources required to research her own laboratory data and trace the physiological mechanisms herself. That required time, functional capacity, and the disease not having progressed past the point where sustained analytical work was possible. It required a set of circumstances that most patients in the same situation never reach.

For those who do reach a diagnosis, the cycle does not break. The historical inertia and training gaps identified in previous articles shape treatment as well — and the absence of any commercial infrastructure means nothing is pushing against them. Fixed schedules persist. Dismissed symptoms go unchallenged. Guidelines exist on paper but not in practice.

VII. A Structural Problem, Not a Conspiracy

This article is not an argument about intent. No individual or institution decided that pernicious anemia would be neglected. No one chose to let patients accumulate neurological damage. The pharmaceutical industry did not conspire to suppress B12.

What this article describes is a system that allocates attention through incentive structures, and a treatment that generates none of the signals those structures respond to. The outcome — persistent under-diagnosis, inadequate treatment, preventable and irreversible harm — is not the result of anyone’s malice. It can only be corrected by examining the structural incentives honestly and asking what a system would need to look like in order to address conditions that have no commercial patron. That is a harder problem than identifying a villain. It is also the correct problem.

Pernicious anemia is one of the clearest cases in contemporary medicine where everything required for good outcomes exists — the diagnostic tools, the treatment, the evidence base — and the outcomes remain poor anyway. The gap between what medicine knows and what medicine does is not a gap in knowledge.

It is a gap in the structure of attention. That distinction makes a difference. A gap in knowledge requires discovery. A gap in attention requires only that the right information reach the right people at the right moment — and that those moments accumulate. The science that could end decades of preventable damage already exists. It is waiting for a system that can hear it.

References

Carmel R. Prevalence of undiagnosed pernicious anemia in the elderly. Arch Intern Med. 1996;156(10):1097-1100. PubMed ↩︎
Shipton MJ, Thachil J. Vitamin B12 deficiency – A 21st century perspective. Clin Med (Lond). 2015;15(2):145-150. doi:10.7861/clinmedicine.15-2-145. PMC ↩︎
Lindenbaum J, Healton EB, Savage DG, et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med. 1988;318(26):1720-1728. doi:10.1056/NEJM198806303182604. PubMed ↩︎
Thain A, Visser P, Hart K, et al. Patient-reported characteristics of pernicious anaemia: a first step to initiate James Lind Alliance Priority Setting Partnership driven research. BMC Primary Care. 2025. doi:10.1186/s12875-025-03036-0. PMC ↩︎
National Institute for Health and Care Excellence. Evidence review for information and support: Vitamin B12 deficiency in over 16s: diagnosis and management. NICE Guideline No. 239. 2024. NCBI Bookshelf ↩︎
National Institute for Health and Care Excellence. Vitamin B12 deficiency in over 16s: diagnosis and management. NICE Guideline NG239. Published March 6, 2024. NICE ↩︎
Pernicious Anaemia Society. Treatment of Pernicious Anaemia. pernicious-anaemia-society.org/treatment/ ↩︎
Bhanja D, Zain A, Moeckel C, Waheed A. Trends in Vitamin B12 Level Testing in Patients on Metformin From 2000 to 2020. PRiMER. 2024;8:33. doi:10.22454/PRiMER.2024.278059. Journal ↩︎
Mumtaz H, Ghafoor B, Saghir H, et al. Association of Vitamin B12 deficiency with long-term PPIs use: A cohort study. Ann Med Surg (Lond). 2022. PMC ↩︎

Clinical Reference

Pernicious Anemia: Recognizing and Preventing Irreversible Neurological Damage — Physician reference covering evidence-based treatment protocols, common treatment errors, diagnostic principles, and neurological monitoring. The clinical complement to the structural argument made in this article.

No Market, No Attention: Pernicious Anemia and the Cost of Invisibility